Beam Therapeutics (BEAM) Stock Forecast & Price Target

Compare

1,690 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BEAM Analyst Ratings

Strong Buy

11 Buy

3 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Beam

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BEAM Stock 12 Month Forecast

Average Price Target

$42.67

▲(101.65%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $42.67 with a high forecast of $80.00 and a low forecast of $17.00. The average price target represents a 101.65% change from the last price of $21.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","48":"$48","81":"$81","31.5":"$31.5","64.5":"$64.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,31.5,48,64.5,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.53,22.335384615384616,27.14076923076923,31.946153846153848,36.75153846153846,41.55692307692308,46.362307692307695,51.167692307692306,55.973076923076924,60.77846153846154,65.58384615384615,70.38923076923078,75.19461538461539,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.53,19.463846153846156,21.39769230769231,23.331538461538464,25.26538461538462,27.199230769230773,29.133076923076924,31.06692307692308,33.00076923076924,34.934615384615384,36.868461538461546,38.80230769230769,40.73615384615385,{"y":42.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.53,17.48923076923077,17.44846153846154,17.407692307692308,17.36692307692308,17.326153846153847,17.285384615384615,17.244615384615386,17.203846153846154,17.163076923076922,17.122307692307693,17.08153846153846,17.040769230769232,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.05,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.41,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$42.67

Lowest Price Target$17.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$22.5

Hold

6.33%

Upside

Reiterated

07/11/25

Beam Therapeutics is facing significant financial challenges typical of its industry, reflected in negative earnings and cash flow metrics. However, a recent strategic acquisition and strong technical indicators provide positive momentum. The stock's valuation is hampered by negative earnings, but the acquisition could offer long-term growth opportunities.

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$80

Buy

278.07%

Upside

Reiterated

07/01/25

Beam Therapeutics: Advancements in Gene Editing and Promising Clinical Milestones Justify Buy Rating

Eric JosephJ.P. Morgan

J.P. Morgan

$25.61→$48

Buy

126.84%

Upside

Reiterated

06/25/25

JPMorgan's Bullish Outlook on Beam Therapeutics: Promising Genetic Base-Editing Platform and Strategic Growth Prospects

William PickeringBernstein

Bernstein

$32

Buy

51.23%

Upside

Reiterated

06/19/25

Bernstein Sticks to Its Buy Rating for Beam Therapeutics (BEAM)

Soumit RoyJonesTrading

JonesTrading

$34→$25

Buy

18.15%

Upside

Reiterated

06/17/25

Beam Therapeutics Receives Buy Rating on Promising Sickle Cell Therapy Data and Market Potential

David NierengartenWedbush

Wedbush

$57

Buy

169.38%

Upside

Reiterated

06/16/25

Beam Therapeutics (BEAM) Gets a Buy from Wedbush

Gena WangBarclays

Barclays

$25

Hold

18.15%

Upside

Reiterated

06/16/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (NASDAQ: MRUS) and Beam Therapeutics (NASDAQ: BEAM)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

06/16/25

Beam Therapeutics' BEAM-101 Shows Promising Results in Sickle Cell Disease, Justifying Buy Rating

Dex GenotekAI Firm

AI Firm

$18→$17

Hold

-19.66%

Downside

Reiterated

06/13/25

Alec StranahanBank of America Securities

Bank of America Securities

$43

Buy

103.21%

Upside

Reiterated

06/13/25

Positive Outlook for Beam Therapeutics' BEAM-101 in Sickle Cell Disease Treatment Justifies Buy Rating

Mani ForooharLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/13/25

Bullish Outlook on Beam Therapeutics Driven by Promising Clinical Data and Market Opportunities

Debjit ChattopadhyayGuggenheim

Guggenheim

$78→$55

Buy

159.92%

Upside

Reiterated

05/07/25

Beam Therapeutics Inc (BEAM) PT Lowered to $55 at GuggenheimGuggenheim analyst Debjit Chattopadhyay lowered the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $55.00 (from $78.00) while maintaining a Buy rating.

Kostas BiliourisBMO Capital

BMO Capital

$57→$40

Buy

89.04%

Upside

Reiterated

05/07/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NYSE: NVO), Beam Therapeutics (NASDAQ: BEAM) and TScan Therapeutics (NASDAQ: TCRX)1Q EPS: High-Dose AATD Data & Competitor Updates Remain Investor Focus for 2025

Yanan ZhuWells Fargo

Wells Fargo

$75→$70

Buy

230.81%

Upside

Reiterated

05/06/25

Beam Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating

Luca IssiRBC Capital

RBC Capital

$20

Hold

-5.48%

Downside

Reiterated

05/06/25

RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$22.5

Hold

6.33%

Upside

Reiterated

07/11/25

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$80

Buy

278.07%

Upside

Reiterated

07/01/25

Beam Therapeutics: Advancements in Gene Editing and Promising Clinical Milestones Justify Buy Rating

Eric JosephJ.P. Morgan

J.P. Morgan

$25.61→$48

Buy

126.84%

Upside

Reiterated

06/25/25

JPMorgan's Bullish Outlook on Beam Therapeutics: Promising Genetic Base-Editing Platform and Strategic Growth Prospects

William PickeringBernstein

Bernstein

$32

Buy

51.23%

Upside

Reiterated

06/19/25

Bernstein Sticks to Its Buy Rating for Beam Therapeutics (BEAM)

Soumit RoyJonesTrading

JonesTrading

$34→$25

Buy

18.15%

Upside

Reiterated

06/17/25

Beam Therapeutics Receives Buy Rating on Promising Sickle Cell Therapy Data and Market Potential

David NierengartenWedbush

Wedbush

$57

Buy

169.38%

Upside

Reiterated

06/16/25

Beam Therapeutics (BEAM) Gets a Buy from Wedbush

Gena WangBarclays

Barclays

$25

Hold

18.15%

Upside

Reiterated

06/16/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (NASDAQ: MRUS) and Beam Therapeutics (NASDAQ: BEAM)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

06/16/25

Beam Therapeutics' BEAM-101 Shows Promising Results in Sickle Cell Disease, Justifying Buy Rating

Dex GenotekAI Firm

AI Firm

$18→$17

Hold

-19.66%

Downside

Reiterated

06/13/25

Alec StranahanBank of America Securities

Bank of America Securities

$43

Buy

103.21%

Upside

Reiterated

06/13/25

Positive Outlook for Beam Therapeutics' BEAM-101 in Sickle Cell Disease Treatment Justifies Buy Rating

Mani ForooharLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/13/25

Bullish Outlook on Beam Therapeutics Driven by Promising Clinical Data and Market Opportunities

Debjit ChattopadhyayGuggenheim

Guggenheim

$78→$55

Buy

159.92%

Upside

Reiterated

05/07/25

Kostas BiliourisBMO Capital

BMO Capital

$57→$40

Buy

89.04%

Upside

Reiterated

05/07/25

Yanan ZhuWells Fargo

Wells Fargo

$75→$70

Buy

230.81%

Upside

Reiterated

05/06/25

Beam Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating

Luca IssiRBC Capital

RBC Capital

$20

Hold

-5.48%

Downside

Reiterated

05/06/25

RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Beam Therapeutics

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+6.28%

assigned a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +6.28% per trade.

3 Months

xxx

Success Rate

7/10 ratings generated profit

Average Return

+3.01%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +3.01% per trade.

1 Year

David NierengartenWedbush

Success Rate

5/11 ratings generated profit

Average Return

+15.85%

reiterated a buy rating 27 days ago

Copying David Nierengarten's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +15.85% per trade.

2 Years

xxx

Success Rate

4/10 ratings generated profit

Average Return

-0.50%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -0.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BEAM Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BEAM has received 18 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. BEAM average Analyst price target in the past 3 months is 42.67.

Each month's total comprises the sum of three months' worth of ratings.

BEAM Financial Forecast

BEAM Earnings Forecast

Next quarter’s earnings estimate for BEAM is -$1.11 with a range of -$1.40 to -$0.78. The previous quarter’s EPS was -$1.24. BEAM beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.79% of the time in the same period. In the last calendar year BEAM has Outperformed its overall industry.

BEAM Sales Forecast

Next quarter’s sales forecast for BEAM is $12.77M with a range of $7.47M to $25.00M. The previous quarter’s sales results were $7.47M. BEAM beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 38.64% of the time in the same period. In the last calendar year BEAM has Outperformed its overall industry.

BEAM Stock Forecast FAQ

What is BEAM’s average 12-month price target, according to analysts?

Based on analyst ratings, Beam Therapeutics’s 12-month average price target is 42.67.

What is BEAM’s upside potential, based on the analysts’ average price target?

Beam Therapeutics has 101.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BEAM a Buy, Sell or Hold?

Beam Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.

What is Beam Therapeutics’s price target?

The average price target for Beam Therapeutics is 42.67. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $17.00. The average price target represents 101.65% Increase from the current price of $21.16.

What do analysts say about Beam Therapeutics?

Beam Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of BEAM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Beam Therapeutics (BEAM) Stock Forecast & Price Target

BEAM Analyst Ratings

BEAM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Beam Therapeutics

BEAM Analyst Recommendation Trends

BEAM Financial Forecast

BEAM Earnings Forecast

BEAM Sales Forecast

BEAM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts